Omnicell (NASDAQ:OMCL) Releases Q4 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its fourth quarter earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $0.75-0.80 for the period, compared to the Thomson Reuters consensus estimate of $0.79. The company issued revenue guidance of $240-246 million, compared to the consensus revenue estimate of $243.20 million.

OMCL traded up $1.94 during trading on Thursday, reaching $75.66. 222,900 shares of the company’s stock were exchanged, compared to its average volume of 334,366. Omnicell has a 1 year low of $56.96 and a 1 year high of $92.59. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.03 and a quick ratio of 1.54. The stock has a market capitalization of $3.12 billion, a P/E ratio of 49.45, a price-to-earnings-growth ratio of 2.93 and a beta of 1.12. The company’s fifty day simple moving average is $73.51 and its 200-day simple moving average is $76.82.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.47 by $0.04. Omnicell had a net margin of 5.70% and a return on equity of 11.85%. The company had revenue of $217.40 million during the quarter, compared to analyst estimates of $214.13 million. During the same period last year, the firm posted $0.46 EPS. Omnicell’s revenue for the quarter was up 15.2% compared to the same quarter last year. Equities analysts forecast that Omnicell will post 2.05 EPS for the current year.

A number of equities analysts have issued reports on OMCL shares. ValuEngine lowered shares of Omnicell from a buy rating to a hold rating in a research report on Wednesday, September 4th. BidaskClub raised shares of Omnicell from a hold rating to a buy rating in a research report on Saturday, October 12th. Craig Hallum raised shares of Omnicell from a hold rating to a buy rating and set a $85.00 price target for the company in a research report on Friday, July 26th. Finally, Zacks Investment Research raised shares of Omnicell from a hold rating to a buy rating and set a $79.00 target price for the company in a report on Monday, July 29th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company has an average rating of Buy and a consensus price target of $80.13.

In other news, EVP Scott Peter Seidelmann sold 1,300 shares of Omnicell stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $75.17, for a total transaction of $97,721.00. Following the completion of the transaction, the executive vice president now directly owns 26,333 shares of the company’s stock, valued at approximately $1,979,451.61. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Randall A. Lipps sold 25,926 shares of Omnicell stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $78.03, for a total transaction of $2,023,005.78. Following the transaction, the chief executive officer now directly owns 128,487 shares of the company’s stock, valued at $10,025,840.61. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 40,010 shares of company stock valued at $3,064,563. Insiders own 2.77% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.

See Also: Why are analyst ratings important in trading stocks?

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.